Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis.
Numata T, Endo T, Yanai H, Ota K, Yamamoto Y, Shimizu K, Yamada H, Hayashihara K, Okauchi S, Satoh H, Yamada Y, Tamura T, Saito K, Kikuchi N, Kurishima K, Ishikawa H, Watanabe H, Shiozawa T, Hizawa N, Funayama Y, Hayashi S, Nakamura H, Yamashita T. Numata T, et al. Among authors: yamashita t. In Vivo. 2020 Jul-Aug;34(4):2095-2100. doi: 10.21873/invivo.12013. In Vivo. 2020. PMID: 32606188 Free PMC article.
Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.
Kaburagi T, Kiyoshima M, Nawa T, Ichimura H, Saito T, Hayashihara K, Yamada H, Satoh H, Endo T, Inage Y, Saito K, Inagaki M, Hizawa N, Sato Y, Ishikawa H, Sakai M, Kamiyama K, Kikuchi N, Nakamura H, Furukawa K, Kodama T, Yamashita T, Nomura A, Yoshida S. Kaburagi T, et al. Among authors: yamashita t. Anticancer Res. 2018 May;38(5):3145-3150. doi: 10.21873/anticanres.12577. Anticancer Res. 2018. PMID: 29715155
Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study.
Okauchi S, Numata T, Nawa T, Ichimura H, Saito T, Hayashihara K, Yamada H, Satoh H, Endo T, Inage Y, Kaburagi T, Kiyoshima M, Yamada Y, Tamura T, Saito K, Inagaki M, Hizawa N, Sato Y, Shiozawa T, Sekine I, Ishikawa H, Kurihima K, Sakai M, Kamiyama K, Kimura M, Kikuchi N, Nakamura H, Furukawa K, Kodama T, Miyazaki K, Yamashita T, Hayashi S, Funayama Y, Nomura A. Okauchi S, et al. Among authors: yamashita t. Anticancer Res. 2020 Feb;40(2):957-964. doi: 10.21873/anticanres.14029. Anticancer Res. 2020. PMID: 32014940
Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients.
Miyazaki K, Sato S, Kodama T, Numata T, Endo T, Yamamoto Y, Shimizu K, Yamada H, Hayashihara K, Okauchi S, Satoh H, Yamada Y, Tamura T, Saito K, Kikuchi N, Kurishima K, Ishikawa H, Watanabe H, Shiozawa T, Hizawa N, Funayama Y, Hayashi S, Nakamura H, Yamashita T. Miyazaki K, et al. Among authors: yamashita t. In Vivo. 2020 Jul-Aug;34(4):2001-2007. doi: 10.21873/invivo.11998. In Vivo. 2020. PMID: 32606173 Free PMC article.
Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.
Yamada Y, Tamura T, Yamamoto Y, Ichimura H, Hayashihara K, Saito T, Yamada H, Endo T, Nakamura R, Inage Y, Satoh H, Iguchi K, Saito K, Inagaki M, Kikuchi N, Kurishima K, Ishikawa H, Sakai M, Kamiyama K, Shiozawa T, Hizawa N, Sekine I, Sato Y, Funayama Y, Miyazaki K, Kodama T, Hayashi S, Nomura A, Nakamura H, Furukawa K, Yamashita T, Okubo H, Suzuki H, Kiyoshima M, Kaburagi T. Yamada Y, et al. Among authors: yamashita t. Anticancer Res. 2020 Oct;40(10):5757-5764. doi: 10.21873/anticanres.14592. Anticancer Res. 2020. PMID: 32988903 Clinical Trial.
Atezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI).
Okauchi S, Ohara G, Shiozawa T, Watanabe H, Numata T, Nakamura R, Tamura T, Kikuchi N, Miyazaki K, Hayashi S, Sakurai H, Yamashita T, Kurishima K, Inagaki M, Endo T, Ishikawa H, Kaburagi T, Satoh H, Sakamoto T, Hizawa N. Okauchi S, et al. Among authors: yamashita t. In Vivo. 2023 Sep-Oct;37(5):2203-2209. doi: 10.21873/invivo.13320. In Vivo. 2023. PMID: 37652502 Free PMC article.
Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI).
Tamura T, Numata T, Yanai H, Nakamura R, Shiozawa T, Watanabe H, Okauchi S, Kikuchi N, Miyazaki K, Hayashi S, Yamashita T, Kurishima K, Inagaki M, Satoh H, Ishikawa H, Kaburagi T, Endo T, Sakamoto T, Hizawa N. Tamura T, et al. Among authors: yamashita t. Anticancer Res. 2023 Oct;43(10):4583-4591. doi: 10.21873/anticanres.16652. Anticancer Res. 2023. PMID: 37772562
Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
Tasaka Y, Honda T, Nishiyama N, Tsutsui T, Saito H, Watabe H, Shimaya K, Mochizuki A, Tsuyuki S, Kawahara T, Sakakibara R, Mitsumura T, Okamoto T, Kobayashi M, Chiaki T, Yamashita T, Tsukada Y, Taki R, Jin Y, Sakashita H, Natsume I, Saitou K, Miyashita Y, Miyazaki Y. Tasaka Y, et al. Among authors: yamashita t. Lung Cancer. 2021 May;155:120-126. doi: 10.1016/j.lungcan.2021.03.014. Epub 2021 Mar 22. Lung Cancer. 2021. PMID: 33798901
6,803 results